Farletuzumab
From Wikipedia, the free encyclopedia
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | FR-alpha |
| Clinical data | |
| Routes of administration | Intravenous injection |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6466H9928N1716O2020S42 |
| Molar mass | 145371.06 g·mol−1 |
  (what is this?) (verify) | |
Farletuzumab (MORAb-003) is a humanized monoclonal antibody[1] of IgG1/κ[2] which is being investigated for the treatment of ovarian cancer.[3][4]
This drug was developed by Morphotek, Inc.
It is targeted at folate receptor alpha (FRα) which is overexpressed in some cancers such as epithelial ovarian cancer (EOC) and non-small-cell lung carcinoma.[2]
